Home » Harmonizing U.S., EU Orphan Protocol Guidance Could Speed Access to Therapies
Harmonizing U.S., EU Orphan Protocol Guidance Could Speed Access to Therapies
May 10, 2012
To help drugmakers speed new therapies to patients with rare diseases, U.S. and EU regulators should harmonize their philosophies around orphan drug development and generate common guidance on trial requirements, experts say.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor